Risk of therapy-related leukaemia and preleukaemia after Hodgkin's disease. Relation to age, cumulative dose of alkylating agents, and time from chemotherapy
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
391 patients treated intensively for Hodgkin's disease were followed for up to 15 years to evaluate the risk of therapy-related acute non-lymphocytic leukaemia (t-ANLL) and preleukaemia. Only two independent factors, patient age and cumulative dose of alkylating agents, were related to the risk of t-ANLL. The hazard rate of t-ANLL was roughly proportional to the square of patient age and to the total cumulative dose of alkylating agents. In 320 patients treated with alkylating agents the cumulative risk of t-ANLL increased steadily from 1 year after the start of treatment and reached 13.0% (SE 3.0) at 10 years after which time there were no further cases. Calculated from cessation of therapy with alkylating agents, however, the cumulative risk curve increased steeply during the first 1-2 years then gradually levelled out and no new cases were observed beyond 7 years. With a 15-year follow-up the general risk of solid tumours was not increased.
Originalsprog | Engelsk |
---|---|
Tidsskrift | Lancet |
Vol/bind | 2 |
Udgave nummer | 8550 |
Sider (fra-til) | 83-88 |
Antal sider | 6 |
ISSN | 0140-6736 |
Status | Udgivet - 1987 |
Bibliografisk note
DA - 19870812IS - 0140-6736 (Print)LA - engPT - Comparative StudyPT - Journal ArticlePT - Research Support, Non-U.S. Gov'tRN - 0 (Alkylating Agents)RN - 50-18-0 (Cyclophosphamide)SB - AIMSB - IM
ID: 19371728